Venetoclax & Azacitidine Plus Transplantation in High-Risk Myelodysplastic Neoplasms with Increased Blasts 2 (MDS-IB2)

This study focuses on patients aged 18 and above who have high-risk myelodysplastic neoplasms with increased blasts, a condition where the blood cells do not mature properly. The main goal is to find out how effective a combination of two medications, Venetoclax and Azacitidine, is before patients undergo a stem cell transplant. By using these drugs together, researchers hope to improve patients' conditions enough to make the transplant more successful. This is important because finding a better way to prepare patients for transplantation could lead to better outcomes for those at high risk. Participants in the study receive Venetoclax and Azacitidine in 28-day treatment cycles, either once or twice, depending on their response to the first cycle. The progress is checked using specific criteria to see if the treatment is working. If a patient shows a very good response after the first cycle, they move directly to the transplant stage. If not, they receive a second cycle before potentially undergoing the stem cell transplant. If a transplant is not possible, patients receive standard care and are monitored. The study helps determine how well these treatments prepare patients for the next step in their care.